{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:53:11Z","timestamp":1793303591660,"version":"4.5.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s40265-013-0013-7","type":"journal-article","created":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T04:35:38Z","timestamp":1359606938000},"page":"159-177","source":"Crossref","is-referenced-by-count":421,"title":["Ceftazidime-Avibactam: a Novel Cephalosporin\/\u03b2-lactamase Inhibitor Combination"],"prefix":"10.1007","volume":"73","author":[{"given":"George G.","family":"Zhanel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"Zelenitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe R. S.","family":"Lagac\u00e9-Wiens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Denisuik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred S.","family":"Gin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl J.","family":"Hoban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"3rd","given":"Joseph P.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Karlowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,1]]},"reference":[{"key":"13_CR1","first-page":"323","volume-title":"Principles and practice of infectious diseases","author":"D Andes","year":"2010","unstructured":"Andes D, Craig W. Cephalosporins. In: Mandell G, Bennett J, Dolin R, editors. Principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone Elsevier; 2010. p. 323\u201337.","edition":"7"},{"issue":"3","key":"13_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2165\/11533040-000000000-00000","volume":"70","author":"JD Pitout","year":"2010","unstructured":"Pitout JD. Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs. 2010;70(3):313\u201333.","journal-title":"Drugs"},{"issue":"5","key":"13_CR3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.mib.2010.09.006","volume":"13","author":"K Bush","year":"2010","unstructured":"Bush K. Alarming beta-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr Opin Microbiol. 2010;13(5):558\u201364.","journal-title":"Curr Opin Microbiol"},{"issue":"9","key":"13_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.tim.2006.07.008","volume":"14","author":"DM Livermore","year":"2006","unstructured":"Livermore DM, Woodford N. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol. 2006;14(9):413\u201320.","journal-title":"Trends Microbiol"},{"issue":"Suppl 1","key":"13_CR5","doi-asserted-by":"publisher","first-page":"i29","DOI":"10.1093\/jac\/dkp255","volume":"64","author":"DM Livermore","year":"2009","unstructured":"Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother. 2009;64(Suppl 1):i29\u201336.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"13_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.diagmicrobio.2008.11.004","volume":"63","author":"PJ Turner","year":"2009","unstructured":"Turner PJ. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates. Diagn Microbiol Infect Dis. 2009;63(2):217\u201322.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"13_CR7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1179\/joc.2011.23.5.266","volume":"23","author":"SP Hawser","year":"2011","unstructured":"Hawser SP, Badal RE, Bouchillon SK, et al. Trending eight years of in vitro activity of ertapenem and comparators against Escherichia coli from intra-abdominal infections in North America\u2013SMART 2002\u20132009. J Chemother. 2011;23(5):266\u201372.","journal-title":"J Chemother"},{"issue":"4","key":"13_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.diagmicrobio.2011.03.021","volume":"70","author":"DJ Hoban","year":"2011","unstructured":"Hoban DJ, Nicolle LE, Hawser S, et al. Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009\u20132010. Diagn Microbiol Infect Dis. 2011;70(4):507\u201311.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"13_CR9","unstructured":"Bhattacharya S, Bonnet A, Dedhiya M, et al. inventors; Novexel SA and Forest laboratories holdings, assignees. Polymorphic and pseudopolymorphic forms of a pharmaceutical compound. International patent WO 042560 A2. 2011 April 14."},{"issue":"5","key":"13_CR10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.mib.2011.07.026","volume":"14","author":"K Coleman","year":"2011","unstructured":"Coleman K. Diazabicyclooctanes (DBOs): a potent new class of non-beta-lactam beta-lactamase inhibitors. Curr Opin Microbiol. 2011;14(5):550\u20135.","journal-title":"Curr Opin Microbiol"},{"key":"13_CR11","first-page":"258","volume-title":"Wilson and Gisvold\u2019s textbook of organic medicinal and pharmaceutical chemistry","author":"J Beale","year":"2011","unstructured":"Beale J. Antibacterial antibiotics. In: Beale J, Block J, editors. Wilson and Gisvold\u2019s textbook of organic medicinal and pharmaceutical chemistry. 12th ed. Baltimore: Lippincott Williams & Wilkins; 2011. p. 258\u2013329.","edition":"12"},{"issue":"1","key":"13_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2885.1988.tb00117.x","volume":"11","author":"KA Caprile","year":"1988","unstructured":"Caprile KA. The cephalosporin antimicrobial agents: a comprehensive review. J Vet Pharmacol Ther. 1988;11(1):1\u201332.","journal-title":"J Vet Pharmacol Ther"},{"issue":"Suppl. C","key":"13_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/10.suppl_C.1","volume":"10","author":"GL Dunn","year":"1982","unstructured":"Dunn GL. Ceftizoxime and other third-generation cephalosporins: structure-activity relationships. J Antimicrob Chemother. 1982;10(Suppl. C):1\u201310.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 3","key":"13_CR14","doi-asserted-by":"publisher","first-page":"S237","DOI":"10.1093\/clinids\/8.Supplement_3.S237","volume":"8","author":"HC Neu","year":"1986","unstructured":"Neu HC. Beta-lactam antibiotics: structural relationships affecting in vitro activity and pharmacologic properties. Rev Infect Dis. 1986;8(Suppl. 3):S237\u201359.","journal-title":"Rev Infect Dis"},{"issue":"4","key":"13_CR15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/0732-8893(83)90006-8","volume":"1","author":"HC Neu","year":"1983","unstructured":"Neu HC. Beta-lactamase stability of cefoxitin in comparison with other beta-lactam compounds. Diagn Microbiol Infect Dis. 1983;1(4):313\u20136.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"13_CR16","unstructured":"Miossec C, Merdjan H, Hodgson J. Safety and toxicokinetics of NXL104, a broad spectrum \u03b2-lactamase inhibitor, in the rat [abstract no. F-1461 plus poster]. In: 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16\u201319; Washington (DC)."},{"key":"13_CR17","unstructured":"Miossec C. NXL104 \u03b2-lactamase inhibitor [abstract no. plus oral presentation]. Challenge of antibacterial drug development; 2007 Mar 21\u201322; San Diego, CA."},{"issue":"6","key":"13_CR18","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.mib.2003.10.002","volume":"6","author":"DL Popham","year":"2003","unstructured":"Popham DL, Young KD. Role of penicillin-binding proteins in bacterial cell morphogenesis. Curr Opin Microbiol. 2003;6(6):594\u20139.","journal-title":"Curr Opin Microbiol"},{"issue":"2","key":"13_CR19","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1574-6976.2007.00094.x","volume":"32","author":"W Vollmer","year":"2008","unstructured":"Vollmer W, Blanot D, de Pedro MA. Peptidoglycan structure and architecture. FEMS Microbiol Rev. 2008;32(2):149\u201367.","journal-title":"FEMS Microbiol Rev"},{"issue":"2","key":"13_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1574-6976.2008.00105.x","volume":"32","author":"E Sauvage","year":"2008","unstructured":"Sauvage E, Kerff F, Terrak M, et al. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiol Rev. 2008;32(2):234\u201358.","journal-title":"FEMS Microbiol Rev"},{"issue":"2","key":"13_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/jac\/12.2.119","volume":"12","author":"MV Hayes","year":"1983","unstructured":"Hayes MV, Orr DC. Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother. 1983;12(2):119\u201326.","journal-title":"J Antimicrob Chemother"},{"issue":"17","key":"13_CR22","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1007\/s00018-004-4060-9","volume":"61","author":"K Poole","year":"2004","unstructured":"Poole K. Resistance to beta-lactam antibiotics. Cell Mol Life Sci. 2004;61(17):2200\u201323.","journal-title":"Cell Mol Life Sci"},{"key":"13_CR23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1146\/annurev-micro-090110-102911","volume":"65","author":"K Bush","year":"2011","unstructured":"Bush K, Fisher JF. Epidemiological expansion, structural studies, and clinical challenges of new beta-lactamases from gram-negative bacteria. Annu Rev Microbiol. 2011;65:455\u201378.","journal-title":"Annu Rev Microbiol"},{"issue":"1036","key":"13_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1098\/rstb.1980.0049","volume":"289","author":"RP Ambler","year":"1980","unstructured":"Ambler RP. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci. 1980;289(1036):321\u201331.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"Pt 1","key":"13_CR25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1042\/bj2760269","volume":"276","author":"RP Ambler","year":"1991","unstructured":"Ambler RP, Coulson AF, Frere JM, et al. A standard numbering scheme for the class A beta-lactamases. Biochem J. 1991;276(Pt 1):269\u201370.","journal-title":"Biochem J"},{"issue":"8","key":"13_CR26","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.1073\/pnas.78.8.4897","volume":"78","author":"B Jaurin","year":"1981","unstructured":"Jaurin B, Grundstrom T. ampC cephalosporinase of Escherichia coli K-12 has a different evolutionary origin from that of beta-lactamases of the penicillinase type. Proc Natl Acad Sci USA. 1981;78(8):4897\u2013901.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"21","key":"13_CR27","doi-asserted-by":"publisher","first-page":"7378","DOI":"10.1073\/pnas.84.21.7378","volume":"84","author":"M Ouellette","year":"1987","unstructured":"Ouellette M, Bissonnette L, Roy PH. Precise insertion of antibiotic resistance determinants into Tn21-like transposons: nucleotide sequence of the OXA-1 beta-lactamase gene. Proc Natl Acad Sci USA. 1987;84(21):7378\u201382.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"13_CR28","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1128\/AAC.01009-09","volume":"54","author":"K Bush","year":"2010","unstructured":"Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54(3):969\u201376.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"13_CR29","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1128\/AAC.39.6.1211","volume":"39","author":"K Bush","year":"1995","unstructured":"Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995;39(6):1211\u201333.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"13_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1078\/1438-4221-00198","volume":"292","author":"FK Majiduddin","year":"2002","unstructured":"Majiduddin FK, Materon IC, Palzkill TG. Molecular analysis of beta-lactamase structure and function. Int J Med Microbiol. 2002;292(2):127\u201337.","journal-title":"Int J Med Microbiol"},{"key":"13_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1146\/annurev.mi.45.100191.000345","volume":"45","author":"JM Ghuysen","year":"1991","unstructured":"Ghuysen JM. Serine beta-lactamases and penicillin-binding proteins. Annu Rev Microbiol. 1991;45:37\u201367.","journal-title":"Annu Rev Microbiol"},{"issue":"7","key":"13_CR32","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00775-008-0407-2","volume":"13","author":"A Tamilselvi","year":"2008","unstructured":"Tamilselvi A, Mugesh G. Zinc and antibiotic resistance: metallo-beta-lactamases and their synthetic analogues. J Biol Inorg Chem. 2008;13(7):1039\u201353.","journal-title":"J Biol Inorg Chem"},{"issue":"12","key":"13_CR33","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1128\/AAC.39.12.2593","volume":"39","author":"JR Knox","year":"1995","unstructured":"Knox JR. Extended-spectrum and inhibitor-resistant TEM-type beta-lactamases: mutations, specificity, and three-dimensional structure. Antimicrob Agents Chemother. 1995;39(12):2593\u2013601.","journal-title":"Antimicrob Agents Chemother"},{"key":"13_CR34","unstructured":"Docquier J, Stachyra T, Benvenuti M, et al. High resolution crystal structure of CTX-M-15 in complex with the new \u03b2-lactamase inhibitor NXL104 [abstract no. C1-1098 plus oral presentation]. In: 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12\u201315; San Francisco (CA)."},{"issue":"22","key":"13_CR35","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1021\/bi300508r","volume":"51","author":"H Xu","year":"2012","unstructured":"Xu H, Hazra S, Blanchard JS. NXL104 irreversibly inhibits the beta-lactamase from Mycobacterium tuberculosis. Biochemistry. 2012;51(22):4551\u20137.","journal-title":"Biochemistry"},{"key":"13_CR36","unstructured":"Docquier J, Benvenuti M, De Luca F, et al. Structure of the TRU-1 class C and OXA-10 class D \u03b2-lactamases in complex with NXL104: structural basis for broad-spectrum inhibition [abstract no. C1-1427 plus poster]. In: 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010 Sep 12\u201315; Boston (MA)."},{"key":"13_CR37","unstructured":"Docquier J, Benvenuti M, De Luca F, et al. X-ray crystal structure of the Klebsiella pneumoniae OXA-48 class D carbapenemase inhibited by NXL104 [abstract no. C1-640 plus poster]. In: 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010 Sep 12\u201315; Boston (MA)."},{"issue":"Suppl. 4","key":"13_CR38","first-page":"S125","volume":"17","author":"J Docquier","year":"2011","unstructured":"Docquier J, Benvenuti M, Bruneau J, et al. X-ray crystal structure of the Acinetobacter baumannii OXA-24\/40 Class D carbapenemase inhibited by NXL104 [abstract no. P609]. Clin Microbiol Infect. 2011;17(Suppl. 4):S125. Plus poster presented at 21st European Congress of Clinical Microbiology and Infectious Diseases; 2011 May 7\u201310; Milan.","journal-title":"Clin Microbiol Infect"},{"issue":"29","key":"13_CR39","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.1073\/pnas.1205073109","volume":"109","author":"DE Ehmann","year":"2012","unstructured":"Ehmann DE, Jahic H, Ross PL, et al. Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor. Proc Natl Acad Sci USA. 2012;109(29):11663\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"13_CR40","unstructured":"Stachyra T, Pechereau M, Bruneau J, et al. The nature of inhibition of TEM-1 \u03b2-Lactamase by the non-\u03b2-Lactam inhibitor NXL104 [abstract no. C1-1374 plus poster]. In: 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12\u201315; San Francisco (CA)."},{"issue":"12","key":"13_CR41","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1128\/AAC.00568-10","volume":"54","author":"T Stachyra","year":"2010","unstructured":"Stachyra T, Pechereau MC, Bruneau JM, et al. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor. Antimicrob Agents Chemother. 2010;54(12):5132\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"13_CR42","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/jac\/dkh358","volume":"54","author":"A Bonnefoy","year":"2004","unstructured":"Bonnefoy A, Dupuis-Hamelin C, Steier V, et al. In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor. J Antimicrob Chemother. 2004;54(2):410\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"13_CR43","unstructured":"Miossec C, Claudon M, Platel D, et al. The \u03b2-lactamase inhibitor NXL104 does not induce ampC \u03b2-lactamase expression in Enterobacter cloacae: evaluation of ampC expression by quantitative polymerase chain reaction (Q-PCR) [abstract no. F-128 plus poster]. In: 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27\u201330; San Francisco (CA)."},{"issue":"6","key":"13_CR44","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1093\/jac\/dks079","volume":"67","author":"DM Livermore","year":"2012","unstructured":"Livermore DM, Mushtaq S, Barker K, et al. Characterization of beta-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline\u00a0+\u00a0avibactam (NXL104). J Antimicrob Chemother. 2012;67(6):1354\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"13_CR45","unstructured":"Li M, Conklin B, Bonomo R, et al. Effect of N152G substitution of CMY-2 \u03b2-lactamase activity and inhibition [abstract no. A-1012 plus poster]. In: 111th General Meeting of the American Society of Microbiology; 2011 May 21\u201324; New Orleans (LA)."},{"key":"13_CR46","unstructured":"Skalweit M, Li M, Conklin B, et al. Effect of N152G, S and T substitution on CMY-2 \u03b2-lactamase activity and inhibition [abstract no. C1-601 plus poster]. In: 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011 Sep 17\u201320; Chicago (IL)."},{"key":"13_CR47","unstructured":"Aktas Z, Kayacan C, Oncul O. In vitro activity of NXL104 in combination with \u03b2-lactams against Gram-negative bacteria, including OXA-48 beta-lactamase producing Klebsiella pneumoniae [abstract no. E-808 plus poster]. In: 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010 Sep 12\u201315; Boston (MA)."},{"issue":"1","key":"13_CR48","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ijantimicag.2011.09.012","volume":"39","author":"Z Aktas","year":"2012","unstructured":"Aktas Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with beta-lactams against Gram-negative bacteria, including OXA-48 beta-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents. 2012;39(1):86\u20139.","journal-title":"Int J Antimicrob Agents"},{"key":"13_CR49","unstructured":"Biedenbach D, Konrardy M, Sader H, et al. In vitro activity of ceftazidime\/NXL104 against pathogens collected during a phase II complicated urinary tract infection (cUTI) clinical trial [abstract no. E-137 plus poster]. In: 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011 Sep 17\u201320; Chicago (IL)."},{"issue":"Suppl. 2","key":"13_CR50","first-page":"S355","volume":"16","author":"M Castanheira","year":"2010","unstructured":"Castanheira M, Rhomberg P, Jones R, et al. Potent activity of ceftazidime\/NXL104 tested against Enterobacteriaceae isolates carrying multiple \u03b2-lactamase enzymes [abstract no. P 1265]. Clin Microbiol Infect. 2010;16(Suppl. 2):S355. Plus poster presented at 20th European Congress of Clinical Microbiology and Infectious Diseases; 2010 Apr 10\u201313; Vienna.","journal-title":"Clin Microbiol Infect"},{"key":"13_CR51","unstructured":"Crandon J, Banevicius M, Nicolau D. Comparative potency of ceftazidime (CAZ) and ceftazidime-NXL104 (CAZ104) against a resistant population of clinical Pseudomonas aeruginosa (PSA) isolates [abstract no. 585 plus poster]. In: 49th Annual Meeting of the Infectious Diseases Society of America; 2011 Sep 12\u201315; Boston (MA)."},{"issue":"8","key":"13_CR52","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1128\/AAC.00641-09","volume":"53","author":"A Endimiani","year":"2009","unstructured":"Endimiani A, Choudhary Y, Bonomo RA. In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother. 2009;53(8):3599\u2013601.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"13_CR53","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1586\/14787210.5.3.365","volume":"5","author":"A Gin","year":"2007","unstructured":"Gin A, Dilay L, Karlowsky JA, et al. Piperacillin-tazobactam: a beta-lactam\/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther. 2007;5(3):365\u201383.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"13_CR54","unstructured":"Lagac\u00e9-Wiens P, Simner P, Tailor F, et al. Activity of ceftazidime (CAZ)\/NXL104 (CAZ104) versus CAZ alone and other comparators against 4548 Gram-negative bacilli\u2014results from CANWARD 2009-10 [abstract no. E-1816 plus poster]. In: 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011 Sep 17\u201320; Chicago (IL)."},{"issue":"5","key":"13_CR55","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1128\/AAC.01722-10","volume":"55","author":"PR Lagace-Wiens","year":"2011","unstructured":"Lagace-Wiens PR, Tailor F, Simner P, et al. Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrob Agents Chemother. 2011;55(5):2434\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"13_CR56","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1128\/AAC.06064-11","volume":"56","author":"P Levasseur","year":"2012","unstructured":"Levasseur P, Girard AM, Claudon M, et al. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother. 2012;56(3):1606\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"13_CR57","unstructured":"Levasseur P, Miossec C, Girard A, et al. In vitro antibacterial activity of ceftazidime (CAZ) in combination with the \u03b2-lactamase inhibitor, NXL104 [abstract no. E-186 plus poster]. In: 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12\u201315; San Francisco (CA)."},{"issue":"1","key":"13_CR58","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1128\/AAC.00756-10","volume":"55","author":"DM Livermore","year":"2011","unstructured":"Livermore DM, Mushtaq S, Warner M, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2011;55(1):390\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"13_CR59","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1093\/jac\/dkq306","volume":"65","author":"S Mushtaq","year":"2010","unstructured":"Mushtaq S, Warner M, Livermore DM. In vitro activity of ceftazidime\u00a0+\u00a0NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother. 2010;65(11):2376\u201381.","journal-title":"J Antimicrob Chemother"},{"key":"13_CR60","unstructured":"Sader H, Castanheira M, Farrell J, et al. Antimicrobial activity of ceftazidime\/NXL104 tested against Gram-negative organisms, including multidrug-resistant subjects, causing infections in USA and European medical centers [abstract no. E-811 plus poster]. In: 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010 Sep 12\u201315; Boston (MA)."},{"key":"13_CR61","unstructured":"Sader H, Farrell D, Bell J, et al. Antimicrobial activity of ceftazidime\/NXL104 (CAZ104) tested against Gram-negative organisms causing infections in medical centers from Europe (EU), Latin America (LA) and the Asia-Pacific Region (APAC) [abstract no. C2-1251 plus poster]. In: 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011 Sep 17\u201320; Chicago (IL)."},{"key":"13_CR62","unstructured":"Sahm D, Pillar C, Brown N, et al. Activity of ceftazidime\/NXL104 and select comparators against geographically diverse clinical isolates of Pseudomonas aeruginosa [abstract no. E-194 plus poster]. In: 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12\u201315; San Francisco (CA)."},{"key":"13_CR63","unstructured":"Tailor F, Lagac\u00e9-Wiens P, Simner P, et al. Activity of avibactam (NXL-104) in combination with \u03b2-lactams against molecularly characterized AmpC- and ESBL-producing Escherichia coli and Klebsiella pneumoniae for CANWARD 2007\u20132010 [abstract no. F1-165 plus poster]. In: 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011 Sep 17\u201320; Chicago (IL)."},{"issue":"6","key":"13_CR64","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1128\/AAC.01696-10","volume":"55","author":"A Walkty","year":"2011","unstructured":"Walkty A, DeCorby M, Lagace-Wiens PR, et al. In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob Agents Chemother. 2011;55(6):2992\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"13_CR65","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.diagmicrobio.2010.10.025","volume":"69","author":"GG Zhanel","year":"2011","unstructured":"Zhanel GG, Adam HJ, Low DE, et al. Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007\u20132009 study. Diagn Microbiol Infect Dis. 2011;69(3):291\u2013306.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"7","key":"13_CR66","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2165\/00003495-200969070-00003","volume":"69","author":"GG Zhanel","year":"2009","unstructured":"Zhanel GG, Sniezek G, Schweizer F, et al. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs. 2009;69(7):809\u201331.","journal-title":"Drugs"},{"key":"13_CR67","unstructured":"Borgonovi M, Merdjan H, Girard A, et al. Importance of NXL104 pharmacokinetics (PK) in the pharmacodynamics (PD) of ceftazidime\u00a0+\u00a0NXL104 combinations in an in vitro hollow fiber infection model [abstract no. A-023 plus poster]. In: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2008 Oct 25\u201328; Washington (DC)."},{"issue":"Suppl. 2","key":"13_CR68","first-page":"S199","volume":"13","author":"M Borgonovi","year":"2007","unstructured":"Borgonovi M, Miossec C, Lowther J. The efficacy of ceftazidime combined with NXL104, a novel \u03b2-lactamase inhibitor, in a mouse model of kidney infections induced by \u03b2-lactamase producing Enterobacteriaceae [abstract no. P794]. Clin Microbiol Infect. 2007;13(Suppl. 2):S199\u2013200. Plus poster presented at 17th European Congress of Clinical Microbiology and Infectious Diseases; 2007 Mar 31\u2013Apr 3; Munich.","journal-title":"Clin Microbiol Infect"},{"key":"13_CR69","unstructured":"Cottagnoud P, Merdjan H, Acosta F, et al. Pharmacokinetics of the new \u03b2-lactamase inhibitor NXL104 in an experimental rabbit meningitis model; restoration of the bacteriological efficacy of ceftazidime (CAZ) against a class C producing K. pneumoniae [abstract no. F1-321 plus poster]. In: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17\u201320; Chicago (IL)."},{"key":"13_CR70","unstructured":"Levasseur P, Girard A, Delachaume C, et al. NXL104, a novel \u03b2-lactamase inhibitor, restores the bactericidal activity of ceftazidime against ESBL and AmpC producing strains of Enterobacteriaceae [abstract no. F-127 plus poster]. In: 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27\u201330; San Francisco (CA)."},{"key":"13_CR71","unstructured":"Levasseur P, Girard A, Lavallade L, et al. Efficacy of ceftazidime (CAZ)\/NXL104 combination in murine septicaemia caused by CTX-M-producing Enterobacteriaceae species [abstract no. A1-005 plus poster]. In: 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12\u201315; San Francisco (CA)."},{"key":"13_CR72","unstructured":"Levasseur P, Miossec C, Girard A, et al. Use of NXL104, a \u03b2-lactamase inhibitor, to detect Klebsiella pneumoniae carbapenemase (KPC) in Enterobacteriaceae [abstract no. D-291b plus poster]. In: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2008 Oct 25\u201328; Washington (DC)."},{"issue":"5","key":"13_CR73","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1093\/jac\/dkn320","volume":"62","author":"DM Livermore","year":"2008","unstructured":"Livermore DM, Mushtaq S, Warner M, et al. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases. J Antimicrob Chemother. 2008;62(5):1053\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"13_CR74","first-page":"464","volume":"18","author":"R Mendes","year":"2012","unstructured":"Mendes R, Woosley L, Deshpande L, et al. Characterization of resistance mechanisms and epidemiology of Enterobacteriaceae collected during a phase II clinical trial for ceftazidime-avibactam [abstract no. P1676]. Clin Microbiol Infect. 2012;18(Suppl 3):464. Plus poster presented at 22nd European Congress of Clinical Microbiology and Infectious Diseases; 2012 Mar 31\u2013Apr 3; London.","journal-title":"Clin Microbiol Infect"},{"key":"13_CR75","unstructured":"Merdjan H, Girard A, Miossec C, et al. Pharmacokinetics (PK) and efficacy of ceftazidime (CAZ)\/NXL104 combination in a murine pneumonia model caused by an AmpC-producing Klebsiella pneumoniae [abstract no. A1-006 plus poster]. In: 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12\u201315; San Francisco (CA)."},{"key":"13_CR76","unstructured":"Miossec C, Poirel L, Livermore D, et al. In vitro activity of the new \u03b2-lactamase inhibitor NXL104: restoration of ceftazidime (CAZ) efficacy against carbapenem-resistant Enterobacteriaceae strains [abstract no. F1-318 plus poster]. In: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17\u201320; Chicago (IL)."},{"key":"13_CR77","unstructured":"Mushtaq S, Warner M, Miossec C, et al. NXL104\/cephalosporin combinations vs. Enterobacteriaceae with CTX-M ESBLs [abstract no. F1-319 plus poster]. In: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17\u201320; Chicago (IL)."},{"key":"13_CR78","unstructured":"Pechereau M, Claudon M, Black M, et al. Activit\u00e9 in vitro de NXL104 sur CTX-M-15 et KPC-2: un nouvel inhibiteur de \u03b2-lactamases \u00e0 spectre \u00e9tendu (BLSE) et de carbap\u00e9n\u00e8mases de classe A [abstract no. 468 plus poster]. 28\u00e8me R\u00e9union Interdisciplinaire de Chimioth\u00e9rapie Anti-infectieuse; 2008 Dec 3\u20134; Paris."},{"key":"13_CR79","unstructured":"Pechereau M, Claudon M, Black M, et al. Activit\u00e9 in vitro de NXL104 sur SHV-4: un nouvel inhibiteur des \u03b2-lactamases \u00e0 spectre \u00e9tendu [abstract no. 382 plus poster]. 26\u00e8me R\u00e9union Interdisciplinaire de Chimioth\u00e9rapie Anti-infectieuse; 2006 Dec 7\u20138; Paris."},{"issue":"Suppl. 2","key":"13_CR80","first-page":"S511","volume":"11","author":"J Shackcloth","year":"2005","unstructured":"Shackcloth J, Williams L, Northwood J, et al. In vitro activity of AVE1330A, a novel \u03b2-lactamase inhibitor, in combination with aztreonam or ceftazidime against ceftazidime-resistant isolates of species of the Enterobacteriaceae [abstract no. P1571]. Clin Microbiol Infect. 2005;11(Suppl. 2):S511. Plus poster presented at 15th European Congress of Clinical Microbiology and Infectious Diseases; 2005 Apr 2\u20135; Copenhagen.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"13_CR81","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/jac\/dkp197","volume":"64","author":"T Stachyra","year":"2009","unstructured":"Stachyra T, Levasseur P, Pechereau MC, et al. In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother. 2009;64(2):326\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"13_CR82","unstructured":"Stachyra T, Pechereau M, Petrella S, et al. Activity of the new \u03b2-lactamase inhibitor NXL104 against KPC \u03b2-lactamases [abstract no. F1-320 plus poster]. In: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17\u201320; Chicago (IL)."},{"key":"13_CR83","unstructured":"Weiss W, Pulse M, Endimiani A, et al. Efficacy of NXL104 in combination with ceftazidime in murine infection models [abstract no. B-1339 plus poster]. In: 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12\u201315; San Francisco (CA)."},{"key":"13_CR84","unstructured":"Citron D, Goldstein E. In vitro activity of NXL104\/ceftazidime against \u03b2-lactamase producing anaerobic bacteria [abstract no. E-192 plus poster]. In: 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12\u201315; San Francisco (CA)."},{"issue":"7","key":"13_CR85","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1128\/AAC.01682-10","volume":"55","author":"DM Citron","year":"2011","unstructured":"Citron DM, Tyrrell KL, Merriam V, et al. In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes. Antimicrob Agents Chemother. 2011;55(7):3616\u201320.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"13_CR86","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ijantimicag.2012.02.013","volume":"39","author":"LJ Dubreuil","year":"2012","unstructured":"Dubreuil LJ, Mahieux S, Neut C, et al. Anti-anaerobic activity of a new beta-lactamase inhibitor NXL104 in combination with beta-lactams and metronidazole. Int J Antimicrob Agents. 2012;39(6):500\u20134.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"13_CR87","first-page":"183","volume":"41","author":"G Zhanel","year":"1988","unstructured":"Zhanel G, Brunham R. Third-generation cephalosporins. Can J Hosp Pharm. 1988;41(4):183\u201394.","journal-title":"Can J Hosp Pharm"},{"key":"13_CR88","unstructured":"Merdjan H, Tarral A, Girard A, et al. Safety, single dose pharmacokinetics, and pharmacodynamics of \u03b2-lactamase inhibitor NXL104 in healthy young male adults [abstract no. A-809 plus poster]. In: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17\u201320; Chicago (IL)."},{"issue":"Suppl. 2","key":"13_CR89","first-page":"S466","volume":"16","author":"M Felices","year":"2010","unstructured":"Felices M, Gualano V, Tarral A, et al. Combined population pharmacokinetic analysis of four phase 1 studies with NXL104 [abstract no. P 1599]. Clin Microbiol Infect. 2010;16(Suppl. 2):S466. Plus poster presented at 20th European Congress of Clinical Microbiology and Infectious Diseases; 2010 Apr 10\u201313; Vienna.","journal-title":"Clin Microbiol Infect"},{"key":"13_CR90","unstructured":"Li J, Knebel W, Riggs M, et al. Population pharmacokinetic modeling of ceftazidime (CAZ) and avibactam (AVI) in healthy volunteers and patients with complicated intra-abdominal Infection (cIAI) [abstract no. A-634 plus poster]. In: 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2012 Sep 9\u201312; San Francisco (CA)."},{"issue":"Suppl. 2","key":"13_CR91","first-page":"S465","volume":"16","author":"H Merdjan","year":"2010","unstructured":"Merdjan H, Tarral A, Haazen W, et al. Pharmacokinetics and tolerability of NXL104 in normal subjects and patients with varying degrees of renal insufficiency. [abstract no. P 1598]. Clin Microbiol Infect. 2010;16(Suppl. 2):S465. Plus poster presented at 20th European Congress of Clinical Microbiology and Infectious Diseases; 2010 Apr 10\u201313; Vienna.","journal-title":"Clin Microbiol Infect"},{"key":"13_CR92","unstructured":"Bowker K, Noel A, MacGowan A. Pharmacodynamics of NXL104 plus either ceftaroline or ceftazidine against an AmpC producing Enterobacter spp [abstract no. A2-556 plus poster]. In: 51st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011 Sep 17\u201320; Chicago (IL)."},{"issue":"1","key":"13_CR93","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1128\/AAC.01198-10","volume":"55","author":"A Endimiani","year":"2010","unstructured":"Endimiani A, Hujer KM, Hujer AM, et al. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2010;55(1):82\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"13_CR94","doi-asserted-by":"publisher","first-page":"6137","DOI":"10.1128\/AAC.00851-12","volume":"56","author":"JL Crandon","year":"2012","unstructured":"Crandon JL, Schuck VJ, Banevicius MA, et al. Comparative in vitro and in vivo efficacy of human simulated exposures of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;56(12):6137\u201346.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 4","key":"13_CR95","first-page":"S437","volume":"17","author":"C Lucasti","year":"2011","unstructured":"Lucasti C, Popescu I, Ramesh M, et al. Efficacy and safety of ceftazidime\/NXL104 plus metronidazole vs. meropenem in the treatment of complicated intra-abdominal infections in hospitalised adults [abstract no. P1532]. Clin Microbiol Infect. 2011;17(Suppl. 4):S437. Plus poster presented at 21st European Congress of Clinical Microbiology and Infectious Diseases; 2011 May 7\u201310; Milan.","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"13_CR96","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","volume":"28","author":"J Vazquez","year":"2012","unstructured":"Vazquez J, Gonz\u00e1lez Patz\u00e1n L, Stricklin D, et al. Efficacy and safety of ceftazidime avibactam versus imipenem cilastatin for complicated urinary tract infections including acute pyelonephritis, in hospitalized adults: results of a prospective investigator-blinded randomized study. Curr Med Res Opin. 2012;28(12):1921\u201331.","journal-title":"Curr Med Res Opin"},{"key":"13_CR97","unstructured":"Tarral A, Lipka J, Gyaw S, et al. Effect of age and gender on the pharmacokinetics (PK) and safety of NXL104 in healthy subjects (protocol NXL104\/1004) [abstract no. A1-007 plus poster]. In: 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 Sep 12\u201315; San Francisco (CA)."},{"issue":"Suppl. 3","key":"13_CR98","first-page":"372","volume":"18","author":"J Li","year":"2012","unstructured":"Li J, Edeki T, Das S, et al. Effect of a supratherapeutic dose of ceftazidime-avibactam on the QTc interval in a thorough QT study [abstract no. P1417]. Clin Microbiol Infect. 2012;18(Suppl. 3):372. Plus poster presented at 22nd European Congress of Clinical Microbiology and Infectious Diseases; 2012 Mar 31\u2013Apr 3; London.","journal-title":"Clin Microbiol Infect"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0013-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0013-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0013-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0013-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T16:38:15Z","timestamp":1581957495000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0013-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":98,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["13"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0013-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}